NYSE:MRK   Merck & Company, Inc.
So far, poor news on both the pill and another HIV trial leading to a downgrade...so the January $100's have been beaten down pretty bad. The original thesis was based on news on approval of the COVID pill which the EU is meeting on this week. Will wait for that then reassess...
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.